Nomura Keeps a Buy Rating on Marker Therapeutics Inc (MRKR)

By Ryan Adsit

Nomura analyst Christopher Marai maintained a Buy rating on Marker Therapeutics Inc (MRKRResearch Report) on August 9 and set a price target of $16. The company’s shares closed last Monday at $4.50, close to its 52-week low of $3.97.

Marai said:

“Ph2 AML IND in 3Q19, Data update Pivotal (Accelerated Approval?). The trial will evaluate multiTAAs in post-aHSCT patients in both active and adjuvant settings. We believe post-transplant AML is a logical approach to rapid registration, given promising data to date and potential for accelerated approval. We see three key AML settings with registration potential: r/r post-transplant; MRD(-) post-transplant (taking advantage of the recent FDA guidance document. See also our initiation for more on MulitTAA potential in AML. Our View. MRKR presented data from the TACTOPS trial (NCT03192462, IST) testing MultiTAA in pancreatic cancer (see our note). We were encouraged by the results, noting the difficulty of pancreatic cancer as a solid tumor with low immunogenicity and fibrotic microenvironment.”

According to TipRanks.com, Marai is a 4-star analyst with an average return of 7.0% and a 49.3% success rate. Marai covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Global Blood Therapeutics, and Voyager Therapeutics Inc.

Marker Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $13.67.

See today’s analyst top recommended stocks >>

Based on Marker Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.57 million. In comparison, last year the company had a GAAP net loss of $4.81 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.